Your Ozempic Prescription May Come With a Surprising Bonus: Slower Aging

Key Points:

• GLP-1 drugs like semaglutide and tirzepatide, known for weight loss and blood sugar control, may also slow biological aging by reducing molecular aging markers, according to preliminary research presented by Novo Nordisk and Eli Lilly at an anti-aging conference.
• Novo Nordisk’s analysis showed semaglutide users experienced a 2-4 year slowdown in aging markers, depending on the specific molecular clock and organ studied, while Eli Lilly’s tirzepatide demonstrated similar age-slowing effects based on epigenetic changes.
• These findings have not yet undergone peer review and were conducted by company scientists, with aging clock science still emerging and uncertain in its correlation to real health benefits, especially outside populations with obesity or type 2 diabetes.
• Despite limitations, GLP-1 drugs are known to reduce risks of age-related diseases like heart disease, with animal studies suggesting potential longevity benefits beyond calorie restriction effects.
• Further research, including a federally funded trial on GLP-1’s impact on longevity and healthy aging in people over 60, is underway to clarify the drugs’ anti-aging potential.